GSK Lags Q4 Earnings, Tops Sales, Issues Upbeat '24 Guidance
https://www.zacks.com/stock/news/2218970/gsk-lags-q4-earnings-tops-sales-issues-upbeat-24-guidance?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2218970
Jan 31, 2024 - GSK's revenues benefit from strong growth across all segments, especially the Shingles and RSV vaccines. The company also issues fresh 2024 guidance for all its segments.
0
Top Analyst Reports for Microsoft, Exxon Mobil & Toyota Motor
https://www.zacks.com/commentary/2223276/top-analyst-reports-for-microsoft-exxon-mobil-toyota-motor?cid=CS-ZC-FT-research_daily-2223276
Feb 08, 2024 - Today's Research Daily features new research reports on 16 major stocks, including Microsoft Corporation (MSFT), Exxon Mobil Corporation (XOM) and Toyota Motor Corporation (TM).
0
Why GSK (GSK) is a Top Momentum Stock for the Long-Term
https://www.zacks.com/stock/news/2224825/why-gsk-gsk-is-a-top-momentum-stock-for-the-long-term?cid=CS-ZC-FT-tale_of_the_tape|zacks_education_momentum_score-2224825
Feb 12, 2024 - The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
0
All You Need to Know About Glaxo (GSK) Rating Upgrade to Buy
https://www.zacks.com/stock/news/2231922/all-you-need-to-know-about-glaxo-gsk-rating-upgrade-to-buy?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_12_zacks_rank_upgrade-2231922
Feb 26, 2024 - Glaxo (GSK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
0
Here's Why GSK (GSK) is a Strong Momentum Stock
https://www.zacks.com/stock/news/2233246/here-s-why-gsk-gsk-is-a-strong-momentum-stock?cid=CS-ZC-FT-tale_of_the_tape|zacks_education_momentum_score-2233246
Feb 28, 2024 - Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
0
GSK vs. VRTX: Which Stock Is the Better Value Option?
https://www.zacks.com/stock/news/2236145/gsk-vs-vrtx-which-stock-is-the-better-value-option?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_3-2236145
Mar 05, 2024 - GSK vs. VRTX: Which Stock Is the Better Value Option?
0
Emergent (EBS) Down 16% on Q4 Earnings Miss, Tops on Sales
https://www.zacks.com/stock/news/2237558/emergent-ebs-down-16-on-q4-earnings-miss-tops-on-sales?cid=CS-ZC-FT-analyst_blog|earnings_article-2237558
Mar 07, 2024 - Emergent (EBS) reports mixed earnings for fourth-quarter 2023. The company signs a forbearance agreement with its lenders, effective till April 2023-end.
0
Inflation Remains Sticky in February: 5 Safe Picks
https://www.zacks.com/stock/news/2240004/inflation-remains-sticky-in-february-5-safe-picks?cid=CS-ZC-FT-analyst_blog|investment_ideas-2240004
Mar 13, 2024 - We have narrowed our search to five low-beta stocks with a solid dividend yield. These are: TAP, TSN, TM, GSK and BAH.
0
Has GSK PLC Sponsored ADR (GSK) Outpaced Other Medical Stocks This Year?
https://www.zacks.com/stock/news/2239919/has-gsk-plc-sponsored-adr-gsk-outpaced-other-medical-stocks-this-year?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_1-2239919
Mar 13, 2024 - Here is how GSK (GSK) and Capricor Therapeutics (CAPR) have performed compared to their sector so far this year.
0
Regulus (RGLS) Up 71% on Topline Data from Kidney Disease Study
https://www.zacks.com/stock/news/2240223/regulus-rgls-up-71-on-topline-data-from-kidney-disease-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2240223
Mar 13, 2024 - Data from an early-stage study shows that treatment with Regulus' (RGLS) lead drug shows increased biological activity at a higher dose in patients with autosomal dominant polycystic kidney disease.
0
Page 1>